Home

Peter Barrett

CIK 1291895 · last filed 2026-08-05

Peter Barrett is a corporate insider who has filed 65 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for OBX, was dated Aug 5, 2026. Across all open-market trades the lifetime net is +$884.8K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.5M across reported positions. 13 SEC filings were submitted jointly with ALNYLAM PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.52M

Companies

10

Total Filings

65

Lifetime Open-Market Net

$884.8K

Filer Profile

Reported Address
C/O ALNYLAM PHARMACEUTICALS, INC.
300 THIRD STREET
CAMBRIDGE, MA 02142
Related Filers
ALNYLAM PHARMACEUTICALS, INC. — 13 joint filings, latest 2006-06-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OBX Director — — — $0 1 2026-08-05
RVTY Director 28,293 $124.31 $3.52M $0 4 2026-05-11
SYNLOGIC, INC. (SYBX) Delisted Director — $0.69 — $0 15 2024-01-04
LRMR Director — $3.92 — $0 3 2022-05-12
REVVITY, INC. (PKI) Delisted Director 19,668 $115.24 $2.27M -$2.42M 17 2022-05-09
Larimar Therapeutics, Inc. (ZFGN) Delisted Director 386,944 — — $0 10 2019-06-27
Vitae Pharmaceuticals, Inc (VTAE) Delisted Director 1,099,743 — — $300.0K 2 2014-10-01
SCICLONE PHARMACEUTICALS INC (SCLN) Delisted Director — — — $0 3 2012-06-11
HELICOS BIOSCIENCES CORP (HLCS) Delisted Director 11,851,387 — — $3.00M 6 2009-09-22
MOMENTA PHARMACEUTICALS INC (MNTA) Delisted Director — — — $0 3 2008-06-09

Recent Filings

65 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-05 OBX Grant (A) — $0 EDGAR
2026-05-11 RVTY Grant (A) +2,280 $0 EDGAR
2025-05-01 RVTY Grant (A) +2,412 $0 EDGAR
2024-05-02 RVTY Grant (A) +2,195 $0 EDGAR
2024-01-04 SYNLOGIC, INC. (SYBX) Delisted Grant (A) — $0 EDGAR
2023-07-24 LRMR Notice (144) −8,300 -$26.8K EDGAR
2023-06-26 SYNLOGIC, INC. (SYBX) Delisted Grant (A) — $0 EDGAR
2023-05-17 RVTY Grant (A) +1,738 $0 EDGAR
2023-01-04 SYNLOGIC, INC. (SYBX) Delisted Grant (A) — $0 EDGAR
2022-06-13 SYNLOGIC, INC. (SYBX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 65
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.